orantinib has been researched along with Colorectal Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, YJ; Chun, HG; Chung, HC; Chung, IJ; Han, SW; Kim, JG; Kim, SY; Kim, TW; Kim, YH; Lee, J; Shin, DB; Shin, SJ; Song, HS | 1 |
| Ahn, JB; Chung, HC; Jeung, HC; Jung, M; Kim, HR; Rha, SY; Roh, JK; Shin, SJ | 1 |
| Ellis, LM | 1 |
1 review(s) available for orantinib and Colorectal Neoplasms
| Article | Year |
|---|---|
A targeted approach for antiangiogenic therapy of metastatic human colon cancer.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Colonic Neoplasms; Colorectal Neoplasms; Endothelial Growth Factors; Extracellular Matrix; Humans; Indoles; Integrins; Intercellular Signaling Peptides and Proteins; Lymphokines; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
2 trial(s) available for orantinib and Colorectal Neoplasms
| Article | Year |
|---|---|
A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; C-Reactive Protein; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Indoles; Interleukin-6; Interleukin-8; L-Lactate Dehydrogenase; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxindoles; Oxonic Acid; Platelet-Derived Growth Factor; Propionates; Proto-Oncogene Proteins c-sis; Pyrroles; Tegafur; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2014 |
A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Female; Fibroblast Growth Factors; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxindoles; Oxonic Acid; Platelet-Derived Growth Factor; Propionates; Protein Kinase Inhibitors; Pyrroles; Tegafur; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2012 |